vrsa

Ceftobiprole medocaril (BAL5788), the parenteral prodrug of Ceftobiprole, is a broad-spectrum cephalosporin effective against Methicillin-resistant Staphylococcus aureus (MRSA).

Ceftobiprole (Ro 63-9141) is a β-lactam antibacterial agent that exhibits potent bactericidal activity by binding to PBPs, inhibiting transpeptidation and formation of bacterial cell walls, leading to cell lysis and death, with a MIC90 value of 2 μg/mL against methicillin-resistant Staphylococcus aureus.

AVX 13616, Avexa's leading antibacterial candidate, demonstrates significant in vivo antibacterial efficacy, especially against drug-resistant Staphylococcus pathogens, with an IC50 value of 2-4 µg/ml (MICs) and is targeted as an antibacterial agent. Comparable in activity to mupirocin within a nasal decolonization model, AVX13616 necessitated only a single application for effectiveness. This compound, alongside others, exhibited broad-spectrum antibacterial action, achieving MICs of 2-4 micrograms per milliliter against various isolates, including S. aureus, coagulase-negative staphylococci, enterococci, MRSA, VISA, and VRSA. Aimed for topical use and the treatment of wound infection or catheter-related infections, a solitary 5% (w/w) AVX13616 application (roughly equivalent to 2% mupirocin) proved as efficacious as twice-daily 2% mupirocin over five days in decolonizing MRSA in mice.

Antibacterialagent 280 (Compound 7af) is an antimicrobial compound designed specifically to target methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). It shows promise for research applications involving S. aureus infections.

Antibacterialagent 313 (Compound 20) is a broad-spectrum antibacterial agent. It demonstrates potent inhibitory effects against Gram-positive bacteria, with a minimum inhibitory concentration (MIC) of 0.125 μg/mL for Staphylococcus aureus (ATCC 29213) and MIC values between 0.125-0.5 μg/mL for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA) clinical isolates. Additionally, Antibacterialagent 313 also shows inhibitory activity against certain Gram-negative bacteria, such as Escherichia coli (ATCC 25922), with an MIC of 3.03 μg/mL. The compound exhibits low cytotoxicity to CHO-K1 cells, with an IC50 value of 9 μg/mL, making it a useful candidate for bacterial infection research.

14-methyl Pentadecanoic acid methyl ester is a methylated fatty acid methyl ester that has been found in S. zeai sea sponges as the fatty acyl component of zeamide, A. indica leaf extract, and C. vulgaris and H. pluvialis microalgae. It is a major component of the vancomycin-induced biofilm produced by vancomycin-resistant S. aureus (VRSA). 14-methyl Pentadecanoic acid methyl ester has been used as a standard for the quantification of 14-methyl pentadecanoic acid in various foods by GC-MS.

NusB-IN-1 (Compound 22r) is a highly effective, orally administered bacterial rRNA synthesis inhibitor with potent antimicrobial activity against MRSA and VRSA [1].

Antibacterial agent 75 (compound 24) exhibits antibacterial properties and notably re-sensitizes VRSA (Vancomycin-Resistant Staphylococcus aureus) strains to vancomycin, as reported in reference [1].

Ceftobiprole medocaril sodium (BAL5788) is a parenteral prodrug of Ceftobiprole, a pyrrolidinone cephalosporin administered intravenously. As a broad-spectrum cephalosporin, Ceftobiprole exhibits high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococci (VRSA), and penicillin-resistant Streptococci. Additionally, it is effective in inhibiting both gram-positive and gram-negative pathogens.

Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). These components act synergistically to inhibit bacterial protein synthesis. Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA), and Vancomycin-resistant Enterococcus faecium (VREF).